Drug intelligence / Profile preview

INCB013739

Development stage: Phase 2
Lead developer: Incyte
Modality: Small Molecules
Administration: Oral

Overview

INCB013739 is a small molecule inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), developed by Incyte for the treatment of metabolic diseases such as type 2 diabetes and obesity. By inhibiting 11β-HSD1, the drug reduces the conversion of cortisone to cortisol in tissues, which can improve insulin sensitivity and glycemic control. Clinical studies have shown that INCB013739 improves hepatic and peripheral insulin sensitivity, lowers fasting plasma glucose, total cholesterol, and LDL cholesterol levels in patients with type 2 diabetes. The drug was evaluated as an add-on therapy to metformin in phase 2 clinical trials but has not been approved for any indication[1][2][3][5][6].

Other names: 11beta-HSD1 inhibitor Incyte

Targets

HSD11B1 (11-beta-hydroxysteroid dehydrogenase type 1)

Beyond the preview

Go deeper on INCB013739.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INCB013739.

Explore the full profile